Formulations and Treatment Methods
    2.
    发明申请
    Formulations and Treatment Methods 审中-公开
    制剂和治疗方法

    公开(公告)号:US20070275936A1

    公开(公告)日:2007-11-29

    申请号:US11564026

    申请日:2006-11-28

    IPC分类号: A61K31/56 A61P35/00

    摘要: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, including compositions that comprise a liquid formulation comprising less than about 3% v/v water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using the compounds. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

    摘要翻译: 本发明提供包含式1类固醇的组合物,例如16α-溴-3β-羟基-5α-雄甾烷-17-酮半水合物和一种或多种赋形剂,包括包含低于约3%v / v水的液体制剂的组合物 。 该组合物可用于制备改进的药物制剂。 本发明还提供了间歇给药类固醇化合物的方法,例如16α-溴-3β-羟基-5α-雄甾烷-17-酮的类似物和可用于这种给药方案的组合物。 本发明进一步提供抑制病原体复制,改善与免疫调节异常有关的症状并使用该化合物调节受试者的免疫应答的组合物和方法。 本发明还提供了制备和使用这些免疫调节组合物和制剂的方法。

    Manufacture of a Triiodinated Contrast Agent
    3.
    发明申请
    Manufacture of a Triiodinated Contrast Agent 有权
    制造三碘化对比剂

    公开(公告)号:US20140155648A1

    公开(公告)日:2014-06-05

    申请号:US14128782

    申请日:2012-02-02

    摘要: A new compound, (S)-5-(2-acetoxypropanamido)-2,4,6-triiodoisophthalic acid, of formula II (S)-5-(2-acetoxypropanamido)-2,4,6-triiodoisophthalic acid. Said new compound is of use for the production of triiodinated contrast agent, especially lopamidol, with low content of acetyl and hydroxyacetyl analogs. The new compound may be formed from 5-amino-2,4,6-triiodoisophtalic acid by acylating with (S)-1-chloro-1-oxopropan-2-yl acetate. The new compound may then be converted to the respective acid dichloride by reacting with a chlorinating reagent, which is a further object of the present invention, followed by the amidation with 2-amino-1,3-propanediol and acetate hydrolysis.

    摘要翻译: 新的化合物(S)-5-(2-乙酰氧基丙酰胺)-2,4,6-三碘间苯二甲酸,式II(S)-5-(2-乙酰氧基丙酰氨基)-2,4,6-三碘代邻苯二甲酸。 所述新化合物可用于生产具有低含量乙酰基和羟基乙酰基类似物的三碘化造影剂,特别是洛帕糖醇。 新化合物可以通过用(S)-1-氯-1-氧代丙-2-基乙酸酯酰化形成5-氨基-2,4,6-三碘间苯二酸。 然后可以通过与本发明另一个目的的氯化试剂反应,然后用2-氨基-1,3-丙二醇进行酰胺化和乙酸酯水解反应将新的化合物转化成相应的酰氯。

    Crystalline minocycline base and processes for its preparation
    5.
    发明授权
    Crystalline minocycline base and processes for its preparation 有权
    结晶米诺环素碱及其制备方法

    公开(公告)号:US08258327B2

    公开(公告)日:2012-09-04

    申请号:US12528209

    申请日:2008-02-22

    IPC分类号: C07C237/26

    CPC分类号: C07C237/26

    摘要: The invention provides crystalline minocycline base. In particular, three crystalline polymorphic forms, designated Form I, Form II and Form III, of minocycline base are provided. These are characterized by XRD and IR data. Processes for preparing the new polymorphic forms are also provided. For example, Form I is prepared by dissolving and/or suspending amorphous minocycline base in an organic solvent chosen from ethers followed by crystallization from the mixture.

    摘要翻译: 本发明提供了结晶米诺环素碱。 特别地,提供了三环结构的多晶型形式,称为米诺环素碱的I型,II型和III型。 其特征在于XRD和IR数据。 还提供了制备新多晶型体的方法。 例如,通过将无定形米诺环素碱溶解和/或悬浮在选自醚中的有机溶剂中,然后从混合物中结晶来制备形式I。

    Topical Formulation Containing a Tetracycline and a Method of Treating Skin Infections Using the Same
    6.
    发明申请
    Topical Formulation Containing a Tetracycline and a Method of Treating Skin Infections Using the Same 审中-公开
    包含四环素的局部制剂和使用其的治疗皮肤感染的方法

    公开(公告)号:US20120181201A1

    公开(公告)日:2012-07-19

    申请号:US13380283

    申请日:2010-06-25

    申请人: William Heggie

    发明人: William Heggie

    摘要: A topical formulation comprising a tetracycline comprises two separate parts: (i) a first part comprising a tetracyline in solid form suspended in a first vehicle; and (ii) a second part comprising a second vehicle in which the tetracycline is soluble. Preferably the tetracycline is crystalline minocycline base. Suitably, a neutral vehicle is used for the first part of the formulation. The two parts of the formulation may be packaged in separate containers and are preferably topically applied therefrom simultaneously.

    摘要翻译: 包含四环素的局部制剂包括两个单独的部分:(i)包含悬浮在第一载体中的固体形式的四环丁烷的第一部分; 和(ii)包含可溶于四环素的第二种载体的第二部分。 四环素优选结晶米诺环素碱。 适当地,中性载体用于制剂的第一部分。 制剂的两个部分可以包装在单独的容器中,并且优选同时地局部施用。

    Crystalline Minocycline Base and Processes for its Preparation
    8.
    发明申请
    Crystalline Minocycline Base and Processes for its Preparation 有权
    结晶米诺环素基质及其制备方法

    公开(公告)号:US20100286417A1

    公开(公告)日:2010-11-11

    申请号:US12528209

    申请日:2008-02-22

    IPC分类号: C07C215/88 C07C213/10

    CPC分类号: C07C237/26

    摘要: The invention provides crystalline minocycline base. In particular, three crystalline polymorphic forms, designated Form I, Form II and Form III, of minocycline base are provided. These are characterised by XRD and IR data. Processes for preparing the new polymorphic forms are also provided. For example, Form I is prepared by dissolving and/or suspending amorphous minocycline base in an organic solvent chosen from ethers followed by crystallisation from the mixture.

    摘要翻译: 本发明提供了结晶米诺环素碱。 特别地,提供了三环结构的多晶型形式,称为米诺环素碱的I型,II型和III型。 其特征在于XRD和IR数据。 还提供了制备新多晶型体的方法。 例如,通过将无定形米诺环素碱溶解和/或悬浮在选自醚的有机溶剂中,然后从混合物中结晶来制备形式I。

    METHOD OF SYNTHESIZING MACROLIDE COMPOUNDS
    9.
    发明申请
    METHOD OF SYNTHESIZING MACROLIDE COMPOUNDS 有权
    合成MACROLIDE化合物的方法

    公开(公告)号:US20100145035A1

    公开(公告)日:2010-06-10

    申请号:US12604618

    申请日:2009-10-23

    IPC分类号: C07H17/08

    CPC分类号: C07H17/08

    摘要: The present invention relates to methods for synthesizing macrolide compounds which are known to have antibacterial activity, and are useful in the therapy of bacterial infections in mammals. More specifically, the invention relates to methods for synthesizing the macrolide antibiotic, gamithromycin utilizing a novel configuration of catalysts, chemical structures, and/or methods. An embodiment of the present invention may include allowing multiple chemical reactions to proceed without the isolation of chemical intermediates. Thus, multiple reactions may occur in one reaction vessel allowing for a considerable decrease in the cycle-time. The present invention also provides a novel method for inhibiting degradation while isolating a structure of a pharmaceutical composition.

    摘要翻译: 本发明涉及已知具有抗菌活性的大环内酯类化合物的合成方法,可用于哺乳动物细菌感染的治疗。 更具体地说,本发明涉及利用催化剂的新型结构,化学结构和/或方法合成大环内酯类抗生素,吡咯霉素的方法。 本发明的一个实施方案可以包括允许多个化学反应进行而不隔离化学中间体。 因此,在一个反应​​容器中可能发生多次反应,允许循环时间显着降低。 本发明还提供了用于在分离药物组合物的结构的同时抑制降解的新方法。

    Process for the manufacture of iohexol
    10.
    发明授权
    Process for the manufacture of iohexol 有权
    制备碘海醇的方法

    公开(公告)号:US07541494B2

    公开(公告)日:2009-06-02

    申请号:US12094589

    申请日:2006-03-03

    IPC分类号: C07C233/65

    CPC分类号: C07C231/08 C07C237/46

    摘要: A process for the production of iohexol comprises alkylating 5-Acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide using 2(2-methoxy-ethoxy)-ethanol as solvent in the presence of a base, and optionally isolating crude iohexol from the reaction mixture. Preferably, the alkylating agent is 1-chloro-2,3 propanediol and the base is an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide.

    摘要翻译: 制备碘海醇的方法包括使用2(2-甲氧基 - 乙氧基) - 乙醇作为溶剂使5-乙酰氨基-N,N'-双(2,3-二羟基丙基)-2,4,6-三碘间苯二酰胺烷基化, 的碱,并且任选地从反应混合物中分离粗己烯醇。 优选地,烷基化剂是1-氯-2,3丙二醇,碱是碱金属氢氧化物如氢氧化钠或氢氧化钾。